Redundant contribution of a Transient Receptor Potential cation channel Member 1 exon 11 single nucleotide polymorphism to equine congenital stationary night blindness by unknown
RESEARCH ARTICLE Open Access
Redundant contribution of a Transient
Receptor Potential cation channel Member
1 exon 11 single nucleotide polymorphism
to equine congenital stationary night
blindness
Michelle L. Scott1, Emily E. John1, Rebecca R. Bellone2, John C. H. Ching1, Matthew E. Loewen1,
Lynne S. Sandmeyer3, Bruce H. Grahn3 and George W. Forsyth1*
Abstract
Background: Congenital stationary night-blindness (CSNB) is a recessive autosomal defect in low-light vision in
Appaloosa and other horse breeds. This condition has been mapped by linkage analysis to a gene coding for the
Transient Receptor Potential cation channel Member 1 (TRPM1). TRPM1 is normally expressed in the ON-bipolar cells
of the inner nuclear layer of the retina. Down-regulation of TRPM1 expression in CSNB results from a
transposon-like insertion in intron 1 of the TRPM1 gene. Stop transcription signals in this transposon significantly
reduce TRPM1 primary transcript levels in CSNB horses. This study describes additional contributions by a second
mutation of the TRPM1 gene, the ECA1 108,249,293 C > T SNP, to down-regulation of transcription of the TRPM1
gene in night-blind horses. This TRPM1 SNP introduces a consensus binding site for neuro-oncological ventral
antigen 1 (Nova-1) protein in the primary transcript. Nova-1 binding disrupts normal splicing signals, producing
unstable, non-functional mRNA transcripts.
Results: Retinal bipolar cells express both TRPM1 and Nova-1 proteins. In vitro addition of Nova-1 protein retards
electrophoretic migration of TRPM1 RNA containing the ECA1 108,249,293 C > T SNP. Up-regulating Nova-1
expression in primary cultures of choroidal melanocytes carrying the intron 11 SNP caused an average log 2-fold
reduction of ~6 (64-fold) of TRPM1 mRNA expression.
Conclusions: These finding suggest that the equine TRPM1 SNP can act independently to reduce survival of
TRPM1 mRNA escaping the intron 1 transcriptional stop signals in CSNB horses. Coexistence and co-inheritance of
two independent TRPM1 mutations across 1000 equine generations suggests a selective advantage for the
apparently deleterious CSNB trait.
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Background
Reduced expression of the transient receptor potential
cation channel, subfamily M, member 1 (TRPM1) in ret-
inal ON bipolar cells causes congenital stationary night-
blindness (CSNB) in Appaloosa, Knabstrupper and other
horse breeds. We have reported an 1800-fold reduction
of TRPM1 mRNA expression in CSNB retinal tissue [1].
ON bipolar cells lacking the TRPM1 cation channel are
unable to depolarize in response to mGlu R6 receptor
interaction with its coupled Gαo protein, interrupting
signal transmission to the optic nerve [2, 3]. This failure
of depolarization eliminates the b wave in the electro-
retinogram, providing a distinctive clinical signature for
impaired night-vision in affected horses. Inherited de-
fects in TRPM1 channel expression or function produce
this CSNB phenotype.
TRPM1 protein is also expressed in equine skin mela-
nocytes where it participates in melanin production [4].
However, expression of TRPM1 mRNA is only reduced
~300 fold in non-pigmented skin from CSNB horses.
The coat pattern spotting of heterozygotes and the
“snow cap” phenotype of homozygous CSNB horses
typified in the Appaloosa breed appears to have some
connection to the reduced TRPM1 expression in CSNB
skin [1]. The distinctive spotted coat pattern characteristic
of heterozygotes with a single functional TRPM1 gene ac-
counts for the selective breeding for reduced TRPM1 ex-
pression. But the homozygous TRPM1-negative Snowcap
stallion guaranteed to produce spotted offspring on a solid
Bay mare is night-blind [5]. Interest in the molecular basis
for tissue-specific effects of the equine TRPM1 gene is en-
hanced by their different modes of inheritance and the di-
vergent tissue phenotypes attending heterozygous and
homozygous TRPM1 mutations.
Sequencing the coding and flanking regions of the
TRPM1 gene did not identify a credible cause for re-
duced levels of transcript in CSNB horses [6, 7]. How-
ever, analysis of the CSNB retinal transcriptome revealed
the transposon-like insertion of a retroviral LTR in in-
tron 1 of the TRPM1 gene [8]. This insertion introduces
multiple polyadenylation signals likely to prematurely
truncate the primary CSNB TRPM1 transcript. This
finding accounts for decreased TRPM1 expression, but
fails to explain tissue-specific differences (retina vs skin)
in the extent of reduced TRPM1 expression in homozy-
gous CSNB horses or in tissue specificity for the domin-
ance pattern of the retinal and skin phenotypes of the
TRPM1 mutations. Partial dominance of the Leopard
coat pattern spotting phenotype, but recessive inherit-
ance of night blindness could be connected to tissue-
specific differences in TRPM1 mRNA expression or tis-
sue processing.
Previous to discovery of the retroviral LTR insertion in
intron 1 of the TRPM1 gene we had identified an intronic
mutation associated with CSNB and coat pattern pheno-
types. This ECA1 108,249,293 C > T SNP located in intron
11 of the TRPM1 transcript [6] introduces a binding site
for the tissue-specific neuro-oncological ventral antigen 1
(Nova-1). Nova-1 protein is a splice enhancer which can re-
duce the survival of transcripts carrying its recognition mo-
tifs within their RNA sequence [9]. Nova-1 is expressed at
highest levels in neural tissue such as retina [10] where
TRPM1 expression is particularly affected in the CSNB
condition. However, there is much less Nova-1 expression
in skin; providing a basis for tissue-specific differences in
survival of the TRPM1 transcript carrying the intron 11
SNP.
This manuscript reports in vitro and in situ Nova-1
protein interactions with, and effects on the survival of
mutant mRNA carrying the TRPM1 intron 11 C > T
SNP.
Methods
Primary choroidal melanocyte cultures
Retinal and skin tissue samples were obtained from
horses humanely euthanized for other purposes at the
Veterinary Medical Center of the University of Saskatch-
ewan following the Canadian Council on Animal Care
Guidelines for Experimental Animal Use and approved
by the University of Saskatchewan Animal Care Com-
mittee. Samples for choroidal cell culture, for immuno-
histochemistry, and retinal and skin samples for RNA
isolation were collected from an unaffected (homozy-
gous WT) Appaloosa horse. Tissue was also collected
from a CSNB-affected (homozygous for the TRPM1 in-
tron 11 SNP) horse for RNA isolation and choroidal cell
culture. Collected choroidal cells were placed in cell cul-
ture media (DMEM media containing 10 % fetal bovine
serum, 2 mM L-glutamine, 0.1 mM 3-isobutyl-1-methyl-
xanthine, 16.2 nM phorbol 12-myristate 13-acetate, and
50 μg/mL and 50 units/mL of Penicilllin-Streptomycin)
in six-well plates. Cells were incubated in 5 % CO2 at
37 °C. Upon reaching 90–100 % confluency (7–10 days)
cells were trypsinized and passaged into 75 cm2 flasks.
Cells from passage number 5 (p5) were used in all com-
parisons between the two genotypes of choroidal
melanocytes.
Transfection constructs
Nova 1 expression in cultured choroidal melanocytes was
increased by transfecting cells with human Nova-1 in Ori-
gene’s pCMV6-XL5 expression vector. Microphthalmia-
associated transcription factor, subtype M (MITF-M) ex-
pression was up-regulated by transfecting with an expres-
sion plasmid containing human MITF-M cDNA under
control of a cytomegaloviral (CMV) promoter (a gift of
Dr. Shigeki Shibahara of Tohoku University School of
Medicine, Sendai, Japan) [11].
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Transfections
P5 choroidal melanocytes from a normal and a night blind
Appaloosa horse were plated at a density of 6 × 106 cells
per flask and incubated 24 h. Media was exchanged 2 h
before transfecting with 30 μg of plasmid DNA (Nova-1
pCMV6-XL5 cDNA or MITF-M pRc/CMV). Plasmid
DNA solutions in 2.25 mL 2x BES buffer were mixed with
225 ul saturated CaPO4, incubated exactly 20 min at 20 °C
and added dropwise to recipient cells [12] to produce
three biological replicates for each transfection condition.
Transfected cells were incubated overnight prior to RNA
isolation, cDNA synthesis and q-PCR.
q-PCR
RNA was isolated from tissues and cultured cells using
the Trizol protocol and treated with the Turbo DNase
according to manufacturer’s recommended procedure
(Invitrogen). RNA quantity and quality were tested for
A260/280 absorbance and for size (Agilent 2100 bioana-
lyser). First strand cDNA synthesis was carried out with
ThermoScript reverse transcriptase (Invitrogen) accord-
ing to the manufacturer’s protocol. Intron-spanning pri-
mer pairs specific for TRPM1, Nova-1, MITF-M and β-
actin were designed and tested for efficiency and for
production of respective unique products (Table 1).
qPCR was carried out on an Agilent Mx3005P instru-
ment using SYBR Green for product detection. Relative
quantification (RQ) was calculated using 2-ΔΔCT method
[13] on 6 replicated RT reactions for each condition.
qRT-PCR data were analyzed according Schmittgen and
Livak [14].
Immunohistochemistry
Immunohistochemical staining was conducted at Prairie
Diagnostic Services, Saskatoon, SK on an automated stain-
ing platform (Code-On Histomatic Stainer, Fisher Scientific,
Edmonton, AB, Canada). Heat-induced epitope retrieval
was performed (sodium citrate buffer, pH 6.1) and primary
goat polyclonal antibody (goat anti-Nova-1, Santa Cruz Bio-
technology Inc, Dallas, TX) was used at dilutions of 1:10
and 1:20. Primary antibody-dependent binding of rabbit
anti-goat immunoglobulins was detected with an avidin-
biotin immunoperoxidase complex reagent (Vector Labs;
Burlingame, CA), with 3,3′-diaminobenzidine tetrahydro-
chloride (Electron Microscopy Science, Ft. Washington,
PA) as chromogen.
Gel shift assay
Custom RNA oligomers corresponding to 60 bases span-
ning the TRPM1 intron 11 SNP, or to the positive con-
trol RNA used in Nova-1 binding protocol (Table 2)
were purchased from GE Healthcare Dharmacon. 10 ng
of each RNA oligomer was denatured at 80 °C for 5 min,
cooled to room temperature, then incubated for 30 min
@ 20° with 500 ng of wheat germ recombinant human
Nova-1 protein (Abcam, Toronto, ON Canada) in buffer
containing 0.5 M LiCl, 1 mM MgCl2, 20 mM Tris–HCl
pH 7.6, and 20 ng of yeast tRNA per reaction. Samples
were electrophoresed in TBE running buffer on non-
denaturing Tris-glycine-buffered 8 % polyacrylamide gels
at 75 V for 1.5 h. Four replicate gels were stained in
SYBR gold for 35 min, then imaged for 8 s exposures.
Pixel intensity of fluorescent bands was quantitated with
Image Pro Plus 7.0 software by Media Cybernetics.
GraphPad Prism software was used for unpaired T-test
analyses of output data.
Results
Differences in expression of TRPM1 mRNA reported previ-
ously between retinal tissues from CSNB and control
horses [1] were confirmed in tissues sourced for this study.
TRPM1 mRNA expression (normalized to β-actin) in
Table 1 PCR primers used to amplify human (H s) and equine (E c) cDNA templates
Primer 5′ – 3′ sequence Product bp Efficiency
E c Nova-1 F16 CAA ACT ACC ACC AAG TCC TC
E c Nova-1 R224 CTC ACA GTG ACA ACC CTC TC 209 110 %
E c Nova-1 F1024 GGG ACA TTT GCA TTA GGT AG
E c Nova-1 R1454 ATG GGG TAA AGG AGG GGT TA 431
H s Nova-1 F310 ACA TTG CCA TCT TCC CCA AC
H s Nova 1 R371 TGG AGG TGG TCA TGG GAT CA 62
E c MITF-M F 408 CTT GAT GGA TCC TGC CTT G
E c MITF-M R573 GGG AAA AAT ACA CGC TGT GA 166 110 %
E c βactin F55 GCC GTC TTC CCC TCC AT
E c βactin R135 GCC C AC GTA TGA GTC CTT CTG 81 121 %
E c TRPM1 F2254 GAC GAC ATC TCC CAG GAT CT
E c TRPM1 R2326 TGC TCG TCG TGC TTA TAG GA 73 113 %
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retinal tissue from the ERG-confirmed night-blind (CSNB)
horse used in this study was 0.26 ± .022 % of the expression
level measured in retina of a control horse (Fig. 1).
Expression of mRNA coding for the choroidal melano-
cyte marker protein (and TRPM1 transcription factor)
MITF-M [15, 16], was similar in WT and CSNB retinal
tissue and also between WT and CSNB cultured
melanocytes.
Buckanovich et al. reported that Nova-1 expression is
confined to tissues of neural origin [9]. In this study
Nova 1 cDNA template was identified in retinal RNA by
agarose gel electrophoresis (Fig. 2. lane 1) but was not
detectable after 30 pcr cycles with intron-spanning
primers with equal amounts of cDNA template prepared
from equine skin RNA (lane 2). PCR amplification from
the same cDNA template with a primer pair spanning
the stop codon revealed DNA contamination of the
cDNA template made from RNA treated with DNase.
This difference in Nova 1 mRNA expression between
retina and skin shown in Fig. 2 has been confirmed by
qrtPCR (E.J. data not shown).
Nova-1 expression must co-localize with TRPM1 in the
retinal ON-bipolar cell in order for the Nova-1 binding site
created by the TRPM1 intron 11 SNP to affect processing/
stability of TRPM1 transcripts. Immunohistochemistry with
goat anti-equine Nova-1 antibody shows the presence of
Nova-1 antigen in a subpopulation of bipolar cells in the
inner nuclear layer of equine retina (Fig. 3).
Nova-1 is reported to prefer binding to RNA contain-
ing 2 or 3 repeats of the -UCAU- recognition sequence
motif [10]. Nova-1 binding may also be facilitated by
secondary RNA structure where 5′-UCAU-3′ motifs
occur in the predicted loop of stem-loop structures. M-
fold software predicts that the ECA1 108,249,293 C > T
SNP will lie close to the tip of a loop of a predicted sec-
ondary “hairpin” structure in the primary TRPM1 tran-
script (Fig. 4). The -UCAU- motif produced by the SNP
is in an exposed location (position 39 in the 60-mer)
Table 2 RNA oligomer sequences tested in gel shift assay for interaction with Nova-1 protein. Highlighted –UCAU- motifs are predicted
to interact with the Nova-1 protein
Fig. 1 mRNA expression in night-blind equine retina. Relative expression
of mRNA coding for the three proteins of interest from retina of a night
blind (CSNB) horse, compared to expression in a control horse with
normal night vision. Triplicate qrt-pcr reactions were carried out on
single RNA samples
Fig. 2 Tissue-specific Nova-1 expression. RNA from retina (lanes 1 & 5),
pigmented (lanes 2 & 6) and unpigmented skin (lanes 3 & 7) from a
normal horse was reverse-transcribed using equal amounts of cDNA
template in 30 cycles of PCR. PCR products were separated on agarose
gel electrophoresis and identified by fluorescence with ethidium bromide.
Lanes 1–3 were amplified with intron-spanning primers E c Nova-1 F16
– R224, product length = 209 bp. Lanes 5–7 were amplified with E c
Nova-1 F1024 – R1454 primers spanning the stop codon, ;product
length = 431 bp
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which is likely to be stabilized by extensive complemen-
tary base pairing in the stem region of the oligomer.
The other consensus Nova-1 site at position 57 in the
60-mer occurs in the presumably less accessible stem of
the hairpin in the native WT transcript.
The gel-shift assay result shown in Fig. 5 was used to
test the three synthetic RNA oligonucleotides described
in Table 2 for possible in vitro interactions with Nova-1
protein. Small 53-60-mer synthetic RNA oligomers mi-
grated more rapidly than the yeast tRNA (73–93 nucleo-
tides) used to prevent non-specific RNA-protein binding
to Nova-1, and were lost from the bottom of each lane
prior to staining. The excess yeast tRNA appears as the
intensely-stained band at the bottom of each lane.
Preincubation of Nova 1 protein with a 53 base “positive
control” RNA oligomer containing three tandem repeats of
UCAU recognition sequence (Fig. 5 lane 7) formed a com-
plex which retarded migration of this oligomer in polyacryl-
amide media under the non-denaturing conditions used for
electrophoresis. Even a single occurrence of the UCAU
motif in the WT TRPM1 oligomer (lane 3) was apparently
sufficient to allow Nova-1-dependent-RNA complex forma-
tion and retarded electrophoretic migration.
Fig. 3 Nova-1 expression in equine retina. Immunohistochemical
identification of Nova-1 in equine retinal pigment epithelial cells and
in bipolar cells in the inner nuclear layer. Orientation of retinal cross-
section from lower to upper region is as follows: Choroid, retinal pigment
epithelia, rod and cone photoreceptors, outer nuclear layer, inner nuclear
layer (containing the ON-bipolar cells), ganglionic cell layer, inner
limiting membrane
Fig. 4 M-fold minimal energy model of RNA secondary structure.
Predicted two-dimensional secondary structure with base-pairing of
a synthetic 60-mer transcript spanning the ECA1 108,249,293 C > T
TRPM1 intron 11 SNP. Transcription of the SNP produces the adenine
residue at position 41 in the RNA oligomer
Fig. 5 The effect of the presence of Nova-1 protein on electrophoretic
migration of synthetic RNA oligomers. RNA bands were visualized after
electrophoresis by SYBR-gold fluorescence. Lane 1; Background yeast
tRNA only. Lane 2; TRPM1 WT intron 11 60-mer RNA oligo. Lane 3;
TRPM1 WT intron 11 60-mer RNA oligo plus Nova-1 protein. Lane 4;
TRPM1 CSNB Intron 11 SNP 60mer RNA oligo. Lane 5; TRPM1 CSNB
Intron 11 SNP 60mer RNA oligo plus Nova-1. Lane 6; positive control
60-mer oligo containing 3 UCAU motifs. Lane 7; positive control
60-mer oligo plus Nova-1. Location of RNA-Nova-1 complex with
retarded mobility is indicated by open arrows
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Quantitative pixel intensity measurements of the
CYBR Gold fluorescence products in Fig. 5 showed a
154 ± 34 % increase in fluorescence intensity for the re-
tarded positive control RNA bands containing 3 repeats
of the Nova-1 binding motif (lane 7) in four replicates of
this gel-shift assay compared to the native TRPM1 oligo-
mer bands (lane 3) containing a single copy of the motif.
Insertion of a second –UCAU- Nova-1 target motif cor-
responding to the transcript of the intron 11 SNP into
the pyrimidine-rich area of the 60-mer increased the
fluorescence intensity of the Nova-1- RNA complex in
lane 5 to 157 ± 17 % of that of the native TRPM1 oligo-
mer in the 4 gel-shift replicates. Limits to precise quanti-
tation in this assay make the extent of Nova-1 binding
to the 60-mer TRPM1 oligo containing the CSNB SNP
indistinguishable from Nova-1 binding to the positive
control 53-mer RNA of Buckanovich and Darnell [10]
identified in Table 1.
Evidence for the presence of Nova-1 in retinal inner
nuclear bipolar cells and for physical interactions of
Nova-1 protein with TRPM1 mRNA suggests the possi-
bility of in vivo effects of Nova-1 on TRPM1 mRNA
containing the transcript of the intron 11 SNP. The cul-
tured primary choroidal melanocytes obtained from the
CSNB and from the normal horse were used to investi-
gate this possibility. Melanocyte passage to P5 was ne-
cessary to obtain sufficient cell numbers for replicate
transfections. However melanocyte mRNA expression
diminished significantly (p < 0.001) with successive chor-
oidal melanocyte passage for all three marker genes used
in this study (Fig. 6).
An in situ cell culture model requires sufficient MITF-
M protein to promote TRPM1 expression and Nova-1
protein to interact with the binding motif provided by
the intron 11 SNP. Increased expression of marker
mRNA in de-differentiated melanocyte cultures was ob-
tained by transfecting P5 melanocytes singly with the
vectors expressing MITF-M and Nova-1, and then with
dual transfection to increase expression of both proteins.
Single transfections with MITF-M increased TRPM1 ex-
pression ~4-fold in 3 biological replicate transfections of
WT melanocytes and ~2-fold in CSNB melanocyte cul-
tures (Table 3). Single transfections with Nova-1 had the
opposite effect on TRPM1 mRNA expression, decreasing
WT melanocyte TRPM1 expression 5-fold and decreas-
ing CSNB melanocyte TRPM1 expression 55-fold. The
combined dual transfection reduced WT melanocyte
TRPM1 mRNA expression 14-fold (1/0.072) and CSNB
melanocyte TRPM1 mRNA by ~150-fold (1/0.0068)
(Table 3). These genotype differences in response to dual
transfection were significant at the p < 0.001 level.
Discussion
Nova-1 is a neuron-specific RNA splicing factor that fa-
vors alternative exon inclusion during transcript matur-
ation. Mutations inserting Nova-1 recognition sites into
transcripts expressed in neural tissue could significantly
disrupt normal transcript processing/maturation. Co-
expression of Nova-1 with TRPM1 in bipolar cells in the
neural retina indicates potential trouble for the mutant
TRPM1 transcripts containing the novel Nova-1 binding
site. However, the degree of jeopardy attending generation
of a new Nova-1 binding site could be influenced by ac-
cessibility of the new site to its protein ligand. M-fold
structure predictions for synthetic oligomers constructed
for this study suggest that the TRPM1 intron 11 SNP lies
in an exposed loop area of the nascent transcript, and that
the SNP-induced G >A change to the TRPM1 transcript
helps stabilize this exposed target loop by adding an extra
base pair to the proposed secondary structure. This con-
jectured importance of a new Nova-1 binding site on the
side of a modelled exposed loop is supported by the out-
come of the gel shift results reported above.
The existence of a native WT Nova-1 binding site dis-
tal to the intron 11 SNP is of interest because M-fold
software predicts this Nova-1 binding site to be relatively
inaccessible, located at the base of a “stem” in the sec-
ondary structure. The gel shift finding of enhanced bind-
ing of the mutant CSNB oligomer containing a second
site supports in vivo validity of the M-fold model as the
single Nova-1 site in the stem permits the binding of less
oligomer than the combined two sites corresponding to
the CSNB mutant transcript. As observed by Buckano-
vich and Darnell [9], it is also possible that the combin-
ation of two Nova-1 sites on the SNP-containing
oligomer outweighs the importance of Nova-1 accessibil-
ity to any single site.
One could speculate that greater down-regulation of
TRPM1 mRNA expression in CSNB retina (~1800-fold)
Fig. 6 Reduced expression of tissue-specific choroidal melanocyte
marker genes with cell passage. ΔΔCT values compare mRNA expression
levels measured by q-RT-PCR from six separate flasks of each genotype
of melanocytes at the 5th passage to fresh retinal tissue relative
to β-actin
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compared to skin (~300-fold) might be partially attrib-
uted to localized Nova-1 expression in ON-bipolar cells
in the retina. However, connections of tissue differences
in Nova-1 expression to the dominance of coat pattern
and the recessive inheritance of night blindness are not
apparent.
Transcriptome analysis unequivocally demonstrates
termination of TRPM1 transcripts at polyadenylation
sites in the long terminal repeat (LTR) insertion in in-
tron 1 [8]. This study documents the existence of a sec-
ond mutation that can apparently decrease the
production of TRPM1 mRNA in the CSNB horse. The
co-existence of these two mutations in modern horse
breeds, each of which may be able to independently re-
duce or eliminate the TRPM1 transcript in the ON-
bipolar cell of the retina, is an untoward situation. Link-
age between the intron 1 LTR insertion and the intron
11 SNP has been documented to exist in equine DNA
samples dating to 16,000 years BP [17]. Other than a
genomic proximity of ~60 kb, there is no obvious selec-
tion pressure to preserve this linkage for over 1000
equine generations. The recent finding that some mod-
ern Noriker horses carrying the LTR insert lack the in-
tron 11 SNP demonstrates that a crossover between the
two loci does occur, and that the predicted coat pattern
phenotype expression exists without the intron 11 SNP
[6]. We are not aware of any documented observations
of progeny carrying the other crossover product; the in-
tron 11 SNP without the LTR insert. Such horses should
exist, but may lack the coat color phenotype to attract
attention? So the coat pattern and night-blindness phe-
notypes of the isolated intron 11 SNP remain an issue
for future resolution.
Conclusions
The C > T SNP in intron 11 of the TRPM1 transcript
(ECA1 position 108,249,293) found in CSNB Appaloosa
horses introduces a functional binding site for the tissue-
specific neuro-oncological ventral antigen 1 (Nova-1). The
electrophoretic migration of RNA oligomers containing
the translation product of the SNP is retarded in the pres-
ence of Nova-1 protein. Up-regulating Nova-1 expression
in cell lines containing the intron 11 SNP significantly re-
duces TRPM1 expression. Hence, night-blind Appaloosa
horses have a second independent mutation which may
contribute to reducing the amount of functional TRPM1
transcript in retinal ON-bipolar cells.
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Table 3 Relative amount of TRPM1 mRNA detected in cultured choroidal melanocytes transfected with expression vectors coding
for MITF-M and/or Nova-1 expression. n = 6 replicate rt q-pcr reactions
Effect of transfection on relative TRPM1 mRNA level
Wild type melanocytes LP/LP melanocytes P
ΔΔCT Fold change ΔΔCT Fold change
MITF-M −2.1 ± 0.8 4.3 −0.8 ± 1.9 1.74 0.14
Nova-1 2.3 ± 0.8 0.20 5.8 ± 1.1 0.018 <0.001
MITF-M & Nova-1 3.8 ± 0.3 0.072 7.2 ± 0.9 0.0068 <0.001
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